Effects of Psilocybin on Craving in Nicotine Dependence Trial

Bottom line: A Phase 2 trial is investigating whether psilocybin may be associated with reduced nicotine cravings and changes in brain activity in people with nicotine dependence.

A new Phase 2 trial is exploring whether a single dose of psilocybin can reduce nicotine cravings in people with nicotine dependence. Researchers are also investigating how the drug may influence brain activity and psychological factors related to smoking.

This trial is examining the effects of a single 25 mg dose of psilocybin on nicotine craving in individuals with nicotine dependence. Alongside craving, researchers are measuring changes in brain activity, nicotine use, thoughts about nicotine, motivation to quit, and mental health symptoms. The goal is to better understand the biological and psychological mechanisms that might explain any effects the drug has.

The trial is currently in the planning or recruitment phase and is sponsored by the University of British Columbia. Phase 2 studies typically assess how well an intervention works while continuing to monitor safety in a larger group of people. This trial includes repeated brain imaging (MRI) sessions, similar to those used in a prior study, which allows researchers to compare brain activity and craving before and after psilocybin is administered.

If the trial finds that psilocybin reduces nicotine cravings, it could provide important insights into how the drug affects brain processes involved in nicotine addiction. This knowledge might help develop more targeted and effective treatments for nicotine dependence, offering new options for people trying to quit smoking.

It is important to note that this trial is still in the planning or recruitment phase and has not yet produced any results. Registration on ClinicalTrials.gov does not mean the intervention is effective or safe. Many clinical trials do not meet their goals, and results can take years to become available. Until the trial is completed and the results are published, no conclusions about the efficacy or safety of psilocybin for nicotine dependence can be drawn.

You can track the progress of this trial through the ClinicalTrials.gov record at https://clinicaltrials.gov/study/NCT07852832. Results from the trial will be posted on this site once they become available.

Sources: https://clinicaltrials.gov/study/NCT07852832 (NCT07852832)

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.